Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | ROCK2 | O75116 | 17/20 | 0.56 |
| ▸ | ROCK1 | Q13464 | 7/20 | 0.56 |
| ▸ | CCR2 | P41597 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL807183 | 0.86 | TSHR (0.66) | HTTTSHR | |
| SCHEMBL15081975 | 0.86 | TSHR (0.66) | HTTTSHR | |
| SCHEMBL15084364 | 0.85 | GAA (0.60) | GAAMAPTHTTROCK2ROCK1 | |
| SCHEMBL807582 | 0.81 | GAA (0.56) | GAAMAPTHTTROCK2ROCK1 | |
| SCHEMBL15081995 | 0.79 | ALDH1A1 (0.56) | GAAMAPTHTTTSHR | |
| SCHEMBL13754467 | 0.79 | CACNA1B (0.66) | GAAMAPTHTTROCK2ROCK1 | |
| SCHEMBL14193581 | 0.77 | ROCK2 (0.57) | GAAMAPTHTTROCK2ROCK1 | |
| SCHEMBL14193590 | 0.77 | ROCK2 (0.57) | GAAMAPTHTTROCK2ROCK1 | |
| SCHEMBL19368224 | 0.76 | CHRNB2 (0.60) | MAPTHTTROCK2ROCK1CCR2 | |
| SCHEMBL14193591 | 0.75 | PRKD3 (0.56) | GAAMAPTHTTROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9242981-B2 | Fused pyrazole derivatives as novel ERK inhibitors | MERCK SHARP & DOHME CORP. (US) | 2016-01-26 | — | — | US | disclosed |
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MERCK SHARP & DOHME LLC | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130172341-A1 | FUSED PYRAZOLE DERIVATIVES AS NOVEL ERK INHIBITORS | MAPK1, MAPK3, MAP3K1 | GAA 2994/4885MAPT 3007/4885HTT 4850/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.